LTRN

LTRN

NASDAQ

Lantern Pharma Inc.

1.12

-0.97(-46.41%)
Volume

7.4M

Market Cap

$12.53M

P/E Ratio

-1.65

EPS

$-1.93


Price Chart

Price Alerts

No price alerts set. Add an alert to get notified!

Notify when price goes above $120.00
Notify when price goes above $180.00
Notify when price goes below $180.00

Key Financial Ratios

P/E Ratio

-1.65

P/B Ratio

1.62

EPS

$-1.93

ROE

-98.08%

Profit Margin

0.00%

Operating Margin

0.00%

Peer Comparison

Compare TSM with similar companies in the sector

Company Price Change % P/E Market Cap D/E
ANVS
Annovis Bio, Inc.
$2.03 -5.58% -1.75 $39.94M 0.00
ATNM
Actinium Pharmaceuticals, Inc.
$1.03 -1.90% -0.93 $32.13M 0.08
BCAB
BioAtla, Inc.
$0.15 -9.88% -0.14 $8.98M -0.20
CALC
CalciMedica, Inc.
$0.57 -2.32% -288.93 $8.96M -1.46
ELUT
Elutia Inc.
$1.07 0.00% 0.86 $45.78M 0.40
LVTX
LAVA Therapeutics N.V.
$1.74 -3.87% -2.01 $45.77M 0.00
MAIA
MAIA Biotechnology, Inc.
$1.31 -5.07% -1.88 $50.64M 0.00
RNXT
RenovoRx, Inc.
$1.13 -2.59% -3.73 $41.41M 0.03
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.74 -5.38% -0.12 $2.53M 0.00
TVRD
Tvardi Therapeutics, Inc.
$3.17 -4.80% -2.13 $29.74M 0.01

* Peer stocks are selected based on market capitalization and sector

Private Notes

Key Statistics

52 Week High

$5.74

52 Week Low

$1.11

Dividend

$0.00

Dividend Yield

0.00%

About Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.